Market Cap (In USD)
693.45 Million
Revenue (In USD)
14.01 Million
Net Income (In USD)
-106.8 Million
Avg. Volume
746.32 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.15-30.958
- PE
- -
- EPS
- -
- Beta Value
- 1.822
- ISIN
- US45257U1088
- CUSIP
- 45257U108
- CIK
- 1472012
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Clay B. Siegall Ph.D.
- Employee Count
- -
- Website
- https://immunome.com
- Ipo Date
- 2020-10-02
- Details
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
More Stocks
-
SNG
-
APM
-
3300
-
KALMF
-
000250
-
ZENOTECHZenotech Laboratories Limited
ZENOTECH
-
MHUB
-
PANCHSHEELPanchsheel Organics Limited
PANCHSHEEL